Correction to: BCL2L2 loss renders ‐14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors

Detalles Bibliográficos
Autores principales: Lyu, Yinfeng, Li, Kunping, Li, Yuqing, Wen, Hui, Feng, Chenchen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199167/
https://www.ncbi.nlm.nih.gov/pubmed/37208846
http://dx.doi.org/10.1002/ctm2.1268
_version_ 1785044873590603776
author Lyu, Yinfeng
Li, Kunping
Li, Yuqing
Wen, Hui
Feng, Chenchen
author_facet Lyu, Yinfeng
Li, Kunping
Li, Yuqing
Wen, Hui
Feng, Chenchen
author_sort Lyu, Yinfeng
collection PubMed
description
format Online
Article
Text
id pubmed-10199167
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101991672023-05-21 Correction to: BCL2L2 loss renders ‐14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors Lyu, Yinfeng Li, Kunping Li, Yuqing Wen, Hui Feng, Chenchen Clin Transl Med Erratum John Wiley and Sons Inc. 2023-05-19 /pmc/articles/PMC10199167/ /pubmed/37208846 http://dx.doi.org/10.1002/ctm2.1268 Text en © 2023 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Erratum
Lyu, Yinfeng
Li, Kunping
Li, Yuqing
Wen, Hui
Feng, Chenchen
Correction to: BCL2L2 loss renders ‐14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors
title Correction to: BCL2L2 loss renders ‐14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors
title_full Correction to: BCL2L2 loss renders ‐14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors
title_fullStr Correction to: BCL2L2 loss renders ‐14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors
title_full_unstemmed Correction to: BCL2L2 loss renders ‐14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors
title_short Correction to: BCL2L2 loss renders ‐14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors
title_sort correction to: bcl2l2 loss renders ‐14q renal cancer dependent on bcl2l1 that mediates resistance to tyrosine kinase inhibitors
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199167/
https://www.ncbi.nlm.nih.gov/pubmed/37208846
http://dx.doi.org/10.1002/ctm2.1268
work_keys_str_mv AT lyuyinfeng correctiontobcl2l2lossrenders14qrenalcancerdependentonbcl2l1thatmediatesresistancetotyrosinekinaseinhibitors
AT likunping correctiontobcl2l2lossrenders14qrenalcancerdependentonbcl2l1thatmediatesresistancetotyrosinekinaseinhibitors
AT liyuqing correctiontobcl2l2lossrenders14qrenalcancerdependentonbcl2l1thatmediatesresistancetotyrosinekinaseinhibitors
AT wenhui correctiontobcl2l2lossrenders14qrenalcancerdependentonbcl2l1thatmediatesresistancetotyrosinekinaseinhibitors
AT fengchenchen correctiontobcl2l2lossrenders14qrenalcancerdependentonbcl2l1thatmediatesresistancetotyrosinekinaseinhibitors

Ejemplares similares